Contraindications of incretin therapy: difference between revisions
Diff·revision 1 → 2·11:14, 11 Nov 2024
Difference between revision 1 and revision 2 of Contraindications of incretin therapy. 5 lines changed; the page grew by 588 bytes.
| Revision 1 — 09:00, 1 Nov 2024 Peptide_Pete (talk) start article; incidence figures to follow 1,477 bytes +1,477 | Revision 2 — 11:14, 11 Nov 2024 ClinicCorrespondent (talk) fix a dangling clause 2,065 bytes +588 | ||
|---|---|---|---|
| 10 | The labelled contraindications for the class are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prior serious hypersensitivity to the product or an excipient. The first derives from rodent C-cell findings and is precautionary; see [[Adverse effects of GLP-1 receptor agonists]].{{r|drucker2018}} | 10 | The labelled contraindications for the class are a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prior serious hypersensitivity to the product or an excipient. The first derives from rodent C-cell findings and is precautionary; see [[Adverse effects of GLP-1 receptor agonists]].{{r|drucker2018}} |
| 11 | 11 | ||
| + | 12 | == Labelled contraindications == | |
| + | 13 | The thyroid contraindication is the distinctive one for this class. Rodent studies showed C-cell hyperplasia and tumours at high exposure; human C cells express the receptor at far lower density and no human signal has been established, but the contraindication is retained as a precaution.{{r|drucker2018}} | |
| + | 14 | ||
| + | 15 | Hypersensitivity contraindications are ordinary for any injected peptide and cover both the active substance and excipients. Reactions specific to a formulation component do not necessarily extend to another product containing the same peptide. | |
| + | 16 | ||
| 12 | == References == | 17 | == References == |
| 13 | {{reflist}} | 18 | {{reflist}} |